FDA Pushes Review Time For GSK’s Blood Cancer Therapy Added Via Sierra Oncology Acquisition
The FDA has extended the review period for GSK plc's (NYSE:
Mersana’s UpRi Shows Potential in Ovarian Cancer; Analyst Initiates Coverage with Buy Rating
Guggenheim Partners has initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating
Risankizumab Met Primary And Key Secondary Endpoints In 52-Week Phase 3 Maintenance Study In Ulcerative Colitis Patients
In ulcerative colitis patients with a clinical response to risankizumab induction treatment, a significantly higher proportion of patients treated with risankizumab (180 mg or 360 mg) achieved the primary endpoint of
Why Are Mersana Therapeutics Shares Nosediving Today
The FDA has issued a partial clinical hold pausing new patient enrollment in Mersana Therapeutics Inc's (NASDAQ: MRSN) UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in
Hoth Therapeutics Announces IRB Approval For FDA Cleared First-In-Human Clinical Trial Of HT-001 At Second Clinical Site
Hoth achieves milestone of multiple sites to host trialNEW YORK, June 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced today that it has
Starton Therapeutics Receives Authorization From The FDA To Proceed With STAR-LLD Lenalidomide Phase 1b Clinical Trial In Multiple Myeloma
FDA agrees to the planned Phase 1b study in second-line transplant-ineligible patients in multiple myelomaTreatment regimen will include Velcade® (bortezomib) and dexamethasone and replace oral Revlimid® with
Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia
The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of schizophrenia. This is the first time these capsules will be tried on humans in the U.S
Prospects for Full Approval of Eisai and Biogen’s Leqembi Shine Brighter after FDA Committee Vote
Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) Phase 3 Clarity AD tria
Drug Shortages in Focus: How FDA’s Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March.
Methotrexate is an injected medication utilized to treat various cancers and autoimmune diseases like rheumatoid arthritis, as stated by the National Cancer Institute.
Smith+Nephew Announces 510(K) Clearance Of Its AETOS Shoulder System For Anatomic And Reverse Shoulder Replacement
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its AETOS Shoulder System.Designed